SEC Form 4 · accession 0001127602-17-031636
AMGEN INC · AMGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francois de Carbonnel
Director
Period of report
Nov 8, 2017
Accepted (ET)
Nov 8, 2017 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000318154
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 8, 2017 | S | 4,000 | $173.6055 | D | 15,528 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1$173.6055 is an average price. The prices ranged from $173.57 to $173.64 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- F2These shares include 277 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program, as amended, and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred Restricted Stock Units and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.